Elazzouzi Amy 4
4 · Aura Biosciences, Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
Aura Biosciences SVP Amy Elazzouzi Receives RSU & Option Award
What Happened
Amy Elazzouzi, Senior Vice President, Finance at Aura Biosciences (AURA), was granted a total of 125,000 shares on 2026-03-02 via two awards: 44,528 restricted stock units (RSUs) and 80,472 derivative-share awards. The filing reports an acquisition price of $0.00 per share (standard for equity grants). These are awards (transaction code A), not open-market purchases or sales.
Key Details
- Transaction date: 2026-03-02; Form 4 filed 2026-03-03 (appears timely).
- Grants: 44,528 RSUs (F1) and 80,472 derivative shares (F2) — total 125,000 shares. Reported price for both = $0.00.
- Vesting (from footnotes): RSUs vest in four substantially equal annual installments beginning Jan 15, 2027. The derivative award vests 25% on Feb 1, 2027, then pro rata monthly over 36 months thereafter, subject to continued service.
- Shares owned after transaction: not specified in the provided filing summary.
- No 10b5-1 plan, tax-withholding, or sale reported in this filing.
Context
These entries are grants/awards to an executive and reflect equity compensation with multi-year vesting—common for retention and incentive purposes. Because the awards vest over time, they are not immediately marketable shares. The filing shows acquisition via award (not a purchase or sale), so it should be read as compensation, not a direct bullish or bearish trade signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-02+44,528→ 120,060 total - Award
Stock Option (Right to Buy)
[F2]2026-03-02+80,472→ 80,472 totalExercise: $6.14Exp: 2036-03-02→ Common Stock (80,472 underlying)
Footnotes (2)
- [F1]These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
- [F2]The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.